Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin,Glucagon
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Helmsley Charitable Trust
Deal Size : Undisclosed
Deal Type : Financing
Abvance Gets $3.9M Investment from Helmsley Trust For Insulin-Glucagon Drug
Details : The funding will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate developing to treat diabetes.
Product Name : ABV100
Product Type : Hormone
Upfront Cash : Undisclosed
October 09, 2024
Lead Product(s) : Insulin,Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Helmsley Charitable Trust
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Beta Bionics
Deal Size : Undisclosed
Deal Type : Collaboration
LifeArc Makes Investment to Support Drug Discovery in Sub-Saharan Africa
Details : The collaboration aims for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.
Product Name : Ogluo
Product Type : Peptide
Upfront Cash : Undisclosed
June 05, 2024
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Beta Bionics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $300.0 million
Deal Type : Private Placement
Details : Amphastar intends to use the proceeds for the payment of milestone payments in connection with the acquisition of Baqsimi (glucagon) nasal powder, used to treat very low blood sugar (severe hypoglycemia) in people with diabetes ages 4 years and above.
Product Name : Baqsimi
Product Type : Peptide
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $300.0 million
Deal Type : Private Placement
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Amphastar Pharmaceuticals
Deal Size : $1,075.0 million
Deal Type : Divestment
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
Details : Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.
Product Name : Baqsimi
Product Type : Peptide
Upfront Cash : $625.0 million
June 30, 2023
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Amphastar Pharmaceuticals
Deal Size : $1,075.0 million
Deal Type : Divestment
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Amphastar Pharmaceuticals
Deal Size : $1,075.0 million
Deal Type : Divestment
Lilly to Divest BAQSIMI to Amphastar
Details : Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.
Product Name : Baqsimi
Product Type : Peptide
Upfront Cash : $625.0 million
April 24, 2023
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Amphastar Pharmaceuticals
Deal Size : $1,075.0 million
Deal Type : Divestment
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
Details : Gvoke (glucagon) increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver.
Product Name : Gvoke
Product Type : Peptide
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Arecor
Deal Size : Undisclosed
Deal Type : Agreement
Tetris Pharma Signs Service Agreement With Syneos Health
Details : Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia.
Product Name : Ogluo
Product Type : Peptide
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Arecor
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Glucagon
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : NIDDK
Deal Size : $2.7 million
Deal Type : Funding
Details : This two-year grant will allow AmideBio to select a long-acting soluble stable glucagon candidate and do the necessary work to support the filing of an Investigational New Drug (IND) application with the FDA at the end of the grant period.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
April 10, 2022
Lead Product(s) : Glucagon
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : NIDDK
Deal Size : $2.7 million
Deal Type : Funding
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Arecor
Deal Size : Undisclosed
Deal Type : Acquisition
Xeris’ Commercialization Partner for Ogluo, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
Details : Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. Gvoke® (US) /Ogluo® (EU), the first prescription, ready-to-use, pre-mixed, pre-measured glu...
Product Name : Ogluo
Product Type : Peptide
Upfront Cash : Undisclosed
January 08, 2022
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Arecor
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Product Name : Ogluo
Product Type : Peptide
Upfront Cash : Inapplicable
December 02, 2021
Lead Product(s) : Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable